Delivery Order SPE2DB22D3016-SPE2DB26FAAP0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,609.51 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml Suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $3,198.48 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (60 ml), a liquid formulation of methylphenidate used to treat attention-deficit/hyperactivity disorder. This firm fixed-price, non-set-aside delivery order was competitively awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (60 mL) with a ceiling value of $1,077.54. This non-competitive, firm fixed-price delivery order was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The product is a liquid formulation of methylphenidate used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $1,231.76 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed price delivery order, awarded on September 25, 2025, with an ultimate completion date of September 26, 2025, represents a non-competitive set-aside procurement executed through open competition. The product will be delivered to...
- The Defense Logistics Agency awarded a $3,056.16 firm fixed price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL), a medication used to treat attention deficit hyperactivity disorder. This non-set-aside competitive award was made on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction fulfilling...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.16 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL), a medication used to treat attention deficit hyperactivity disorder. The award was made on July 21, 2025, with a completion date of July 22, 2025, under a firm fixed-price delivery order contract with no set-aside designation. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,814.83 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The award was executed on June 2, 2025, with an ultimate completion date of June 3, 2025, and performance...
- The Defense Logistics Agency awarded a $1,085.70 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAP0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,698.52 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), a liquid formulation of methylphenidate used to treat attention-deficit/hyperactivity disorder. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 27, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As the prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies an extensive range of medications, vaccines, and medical supplies to support military healthcare programs and the Defense Health Agency. The IDC demonstrates the contractor's significant capacity to meet federal pharmaceutical procurement requirements across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 10/24/25 |